Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509.

doi:10.1182/blood-2012-11-466953

ERRATA| December 20, 2012

On page 500 in the 21 July 2011 issue, ther e is an error in the bottom line of Table 1; “CAR-modified T cells” should have read, “TCR gene-modified T cells.” The corrected table is shown.

2012

Full Text

Contents

Data & Figures

Table 1

Immune-mediated toxicities associated with adoptive immunotherapy of cancer

Cell type	Species	Target antigen	Tumor	Toxicities	Reference(s)
CTL	Mouse (or rat)	Pnma-1	Paraneoplastic syndrome (rat)	CNS inflammation	80
CTL		Recoverin	Fibrosarcoma	Retinal dysfunction	81
CTL with IL-2 and vaccine		Various	Melanoma	Melanocyte destruction, ocular toxicity	8,82
CD4⁺ T cells		TRP-1	Melanoma	Vitiligo	83,84
Immune T cells		CEA	Colon	Colitis	85
Transgenic T cells		Telomerase	Prostate	Reduction in B cells	86
TCR transgenic T cells		Various	None	Pancreatitis, colitis	11
CAR-modified T cells		CD19	Lymphoma	Depletion of normal B cells	87,88
CAR-modified T cells		VEGF-R2	Various	Various organs, probably the result of cytokine-induced hypotension	89
TIL and IL-2	Human	Various	Melanoma	Autoimmune thyroiditis, systemic and ocular autoimmunity	90–92
TIL with lymphodepletion and IL-2		Various	Melanoma	Vitiligo, uveitis	9,93
CTL		MART-1	Melanoma	Melanocyte destruction	94
TCR gene–modified T cells		MART-1, gp100	Melanoma	Melanocyte destruction	10
CAR-modified T cells		CAIX	RCC	Liver toxicity (grade 2-4) in 3 of 7 patients; lower grade in 4 of 7 patients with reduced dosing	14
CAR-modified T cells		CD19	Lymphoma	B-cell depletion	15
CAR-modified T cells		Her-2	Colorectal cancer	Lung toxicity	17
TCR gene-modified T cells		CEA	Colorectal cancer	Colitis	19

Cell type	Species	Target antigen	Tumor	Toxicities	Reference(s)
CTL	Mouse (or rat)	Pnma-1	Paraneoplastic syndrome (rat)	CNS inflammation	80
CTL		Recoverin	Fibrosarcoma	Retinal dysfunction	81
CTL with IL-2 and vaccine		Various	Melanoma	Melanocyte destruction, ocular toxicity	8,82
CD4⁺ T cells		TRP-1	Melanoma	Vitiligo	83,84
Immune T cells		CEA	Colon	Colitis	85
Transgenic T cells		Telomerase	Prostate	Reduction in B cells	86
TCR transgenic T cells		Various	None	Pancreatitis, colitis	11
CAR-modified T cells		CD19	Lymphoma	Depletion of normal B cells	87,88
CAR-modified T cells		VEGF-R2	Various	Various organs, probably the result of cytokine-induced hypotension	89
TIL and IL-2	Human	Various	Melanoma	Autoimmune thyroiditis, systemic and ocular autoimmunity	90–92
TIL with lymphodepletion and IL-2		Various	Melanoma	Vitiligo, uveitis	9,93
CTL		MART-1	Melanoma	Melanocyte destruction	94
TCR gene–modified T cells		MART-1, gp100	Melanoma	Melanocyte destruction	10
CAR-modified T cells		CAIX	RCC	Liver toxicity (grade 2-4) in 3 of 7 patients; lower grade in 4 of 7 patients with reduced dosing	14
CAR-modified T cells		CD19	Lymphoma	B-cell depletion	15
CAR-modified T cells		Her-2	Colorectal cancer	Lung toxicity	17
TCR gene-modified T cells		CEA	Colorectal cancer	Colitis	19

CTL indicates cytotoxic T lymphocyte; CNS, central nervous system; IL-2, interleukin-2; and TIL, tumor-infiltrating lymphocytes.

Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509.

ASH Publications

American Society of Hematology

Contents

Data & Figures

Cited By

Email alerts

Amos SM, Duong CPM, Westwood JA, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509.

ASH Publications

American Society of Hematology

Contents

Data & Figures

Related

Related

Cited By

Email alerts

This Feature Is Available To Subscribers Only